Shares of AtriCure Inc. (NASDAQ:ATRC) have received an average rating of “Buy” from the nine ratings firms that are currently covering the company. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $20.75.

A number of equities analysts recently weighed in on ATRC shares. Stifel Nicolaus dropped their price target on AtriCure from $26.00 to $21.00 and set a “buy” rating on the stock in a research note on Friday, August 5th. JMP Securities set a $23.00 target price on AtriCure and gave the company a “buy” rating in a research note on Saturday, August 6th. Canaccord Genuity set a $21.00 target price on AtriCure and gave the company a “buy” rating in a research note on Saturday, August 6th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $17.00 target price (down previously from $22.00) on shares of AtriCure in a research note on Monday, August 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $20.00 target price (down previously from $23.00) on shares of AtriCure in a research note on Monday, August 8th.

In other news, Director Elizabeth D. Krell sold 6,000 shares of AtriCure stock in a transaction dated Tuesday, September 13th. The stock was sold at an average price of $15.93, for a total transaction of $95,580.00. Following the completion of the sale, the director now directly owns 20,162 shares in the company, valued at approximately $321,180.66. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Elizabeth D. Krell sold 5,000 shares of AtriCure stock in a transaction dated Wednesday, August 17th. The shares were sold at an average price of $15.20, for a total value of $76,000.00. Following the sale, the director now owns 15,162 shares of the company’s stock, valued at $230,462.40. The disclosure for this sale can be found here. Insiders own 10.00% of the company’s stock.

A number of large investors have recently bought and sold shares of ATRC. Nuveen Asset Management LLC raised its stake in AtriCure by 2.4% in the first quarter. Nuveen Asset Management LLC now owns 70,965 shares of the medical device company’s stock valued at $1,194,000 after buying an additional 1,636 shares during the period. Perkins Capital Management Inc. raised its stake in AtriCure by 1.1% in the second quarter. Perkins Capital Management Inc. now owns 85,100 shares of the medical device company’s stock valued at $1,202,000 after buying an additional 900 shares during the period. Skylands Capital LLC raised its stake in AtriCure by 68.4% in the second quarter. Skylands Capital LLC now owns 92,597 shares of the medical device company’s stock valued at $1,308,000 after buying an additional 37,597 shares during the period. Essex Investment Management Co. LLC raised its stake in AtriCure by 9.4% in the second quarter. Essex Investment Management Co. LLC now owns 79,076 shares of the medical device company’s stock valued at $1,117,000 after buying an additional 6,818 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in AtriCure by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 134,237 shares of the medical device company’s stock valued at $1,896,000 after buying an additional 4,302 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

AtriCure (NASDAQ:ATRC) opened at 19.95 on Wednesday. The company has a 50-day moving average of $16.96 and a 200 day moving average of $15.58. AtriCure has a 12-month low of $13.44 and a 12-month high of $23.24. The stock’s market cap is $663.12 million.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, October 27th. The medical device company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.07. The firm had revenue of $38.34 million for the quarter, compared to analysts’ expectations of $10.75 million. AtriCure had a negative return on equity of 19.84% and a negative net margin of 23.78%. AtriCure’s revenue was up 22.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.22) EPS. Equities analysts anticipate that AtriCure will post ($1.10) earnings per share for the current year.

About AtriCure

AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

5 Day Chart for NASDAQ:ATRC

Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.